Monthly Communication Report

Organization:	Novo Nordisk Canada Inc.
Associated registration:	954988-360616-22
Communication date:	2025-10-21
Posted date:	2025-11-18

Designated Public Office Holders who participated in the communication:	Daryl Fridhandler, Senator Senate of Canada
List of Details Subject matter Detail Health Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages. Health, Research and Development, Science and Technology Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry. Health, International Trade Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians. Health, International Trade Free trade agreements as they relate to the biopharmaceutical industry. Health Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Responsible Officer who filed this communication report:	Vince Lamanna
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.